$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000161883519000084 Filed on May 07, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.695M	$5.743M	$9.030M
YoY Change	-41.32%	-36.4%	510.14%
% of Gross Profit
Research & Development	$5.246M	$7.889M	$11.96M
YoY Change	-55.67%	-34.03%	503.38%
% of Gross Profit
Depreciation & Amortization	$60.00K	$70.00K	$70.00K
YoY Change	0.0%	0.0%	600.0%
% of Gross Profit
Operating Expenses	$11.94M	$13.63M	$20.99M
YoY Change	-48.62%	-35.04%	327.15%
Operating Profit	-$11.94M	-$13.63M	-$20.99M
YoY Change	-48.62%	-35.04%	327.15%
Interest Expense	-$23.50M	-$4.420M	$30.00K
YoY Change	-78433.33%	-14833.33%	200.0%
% of Operating Profit
Other Income/Expense, Net	-$23.51M	-$4.436M	-$48.07M
YoY Change		-90.77%	-13717.56%
Pretax Income	-$35.45M	-$18.07M	-$69.06M
YoY Change	52.51%	-73.84%	1211.36%
Income Tax	$4.000K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$35.45M	-$18.07M	-$69.06M
YoY Change	52.51%	-73.84%	1210.61%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$965.2K	-$672.2K	-$4.613M
COMMON SHARES
Basic Shares Outstanding	35.37M shares	28.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.70M	$200.0K	$5.000M
YoY Change	122.37%	-96.0%	-48.45%
Cash & Equivalents	$50.68M	$184.0K	$5.029M
Short-Term Investments
Other Short-Term Assets	$1.900M	$1.000M	$2.200M
YoY Change	46.15%	-54.55%	144.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$52.85M	$1.413M	$7.206M
YoY Change	115.93%	-80.39%	-32.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$461.0K	$527.0K	$783.0K
YoY Change	-35.7%	-32.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$622.0K	$649.0K	$1.003M
YoY Change	-36.34%	-35.29%	903.0%
Total Long-Term Assets	$1.566M	$1.821M	$1.786M
YoY Change	-7.56%	1.96%	1686.0%
TOTAL ASSETS
Total Short-Term Assets	$52.85M	$1.413M	$7.206M
Total Long-Term Assets	$1.566M	$1.821M	$1.786M
Total Assets	$54.42M	$3.234M	$8.992M
YoY Change	107.94%	-64.03%	-15.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.567M	$11.93M	$13.31M
YoY Change	7.11%	-10.34%	1230.9%
Accrued Expenses	$7.217M	$11.65M	$12.59M
YoY Change	-35.01%	-7.48%	1698.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$4.000M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.62M	$32.09M	$27.03M
YoY Change	-10.64%	18.68%	1490.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$158.0K
YoY Change		-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$158.0K
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.62M	$32.09M	$27.03M
Total Long-Term Liabilities	$0.00	$0.00	$158.0K
Total Liabilities	$18.62M	$32.09M	$27.28M
YoY Change	-10.94%	17.6%	1504.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$486.7M	-$451.2M	-$376.5M
YoY Change	21.76%	19.84%
Common Stock	$522.5M	$422.4M	$358.2M
YoY Change	29.0%	17.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.79M	-$28.85M	-$18.29M
YoY Change
Total Liabilities & Shareholders Equity	$54.42M	$3.234M	$8.992M
YoY Change	107.94%	-64.03%	-15.96%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$35.45M	-$18.07M	-$69.06M
YoY Change	52.51%	-73.84%	1210.61%
Depreciation, Depletion And Amortization	$60.00K	$70.00K	$70.00K
YoY Change	0.0%	0.0%	600.0%
Cash From Operating Activities	-$19.55M	-$7.678M	-$18.14M
YoY Change	1.88%	-57.67%	885.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$250.0K	$2.150M
YoY Change		-88.37%	21400.0%
Cash From Investing Activities	$0.00	$250.0K	$2.150M
YoY Change		-88.37%	21400.0%
FINANCING ACTIVITIES
Cash Dividend Paid		$200.0K	$200.0K
YoY Change		0.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	70.03M	$6.267M	$19.89M
YoY Change	89.63%	-68.48%
NET CHANGE
Cash From Operating Activities	-19.55M	-$7.678M	-$18.14M
Cash From Investing Activities	0.000	$250.0K	$2.150M
Cash From Financing Activities	70.03M	$6.267M	$19.89M
Net Change In Cash	50.48M	-$1.161M	$3.897M
YoY Change	184.55%	-129.79%	-312.95%
FREE CASH FLOW
Cash From Operating Activities	-$19.55M	-$7.678M	-$18.14M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35367191	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	evfm	Accrued Deferred Offering Costs Current AccruedDeferredOfferingCostsCurrent	130000	USD
CY2018Q4	evfm	Accrued Directors Fees And Related Expenses Current AccruedDirectorsFeesAndRelatedExpensesCurrent	67000	USD
CY2019Q1	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2018Q4	evfm	Notes Issued Stated Rate Monthly Percent Of Principal Permitted NotesIssuedStatedRateMonthlyPercentOfPrincipalPermitted	0.01
CY2018Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	9153000	USD
CY2019Q1	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	9414000	USD
CY2018Q4	evfm	Accrued Deferred Offering Costs Current AccruedDeferredOfferingCostsCurrent	127000	USD
CY2019Q1	evfm	Accrued Directors Fees And Related Expenses Current AccruedDirectorsFeesAndRelatedExpensesCurrent	159000	USD
CY2018Q4	evfm	Accrued Franchise Tax AccruedFranchiseTax	188000	USD
CY2019Q1	evfm	Accrued Franchise Tax AccruedFranchiseTax	50000	USD
CY2018Q4	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	174000	USD
CY2019Q1	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	174000	USD
CY2018Q4	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1117000	USD
CY2019Q1	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1117000	USD
CY2018Q2	evfm	Class Of Warrant Or Right Issued In Transaction ClassOfWarrantOrRightIssuedInTransaction	8500000	shares
CY2019Q1	evfm	Class Of Warrant Or Right Term ClassOfWarrantOrRightTerm	P3Y
CY2018Q1	evfm	Deemed Contribution Upon Exchange Of Preferred Stock DeemedContributionUponExchangeOfPreferredStock	49334000	USD
CY2018Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	392000	USD
CY2019Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	164000	USD
CY2018Q1	evfm	Deferred Rent Adjustment DeferredRentAdjustment	186000	USD
CY2019Q1	evfm	Deferred Rent Adjustment DeferredRentAdjustment	0	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.05
CY2018Q1	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	-47920000	USD
CY2019Q1	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	0	USD
CY2018Q1	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0	USD
CY2019Q1	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	186000	USD
CY2018Q1	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	47920000	USD
CY2018Q1	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	14062000	USD
CY2019Q1	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	10617000	USD
CY2019Q1	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	-30700000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8882000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11933000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11513000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11646000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	549000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	509000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	604000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	670000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	409787000	USD
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	422360000	USD
CY2019Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-6000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	80000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	688000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1962000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	688000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1962000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	11875	shares
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1161000	USD
CY2019Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.68
CY2019Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	475000	shares
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	80	shares
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	37000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2410835	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9865355	shares
CY2018Q4	us-gaap	Assets Assets	4010000	USD
CY2019Q1	us-gaap	Assets Assets	3234000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	2478000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	1413000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	904000	USD
CY2019Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	514000	USD
CY2019Q1	us-gaap	Cash Cash	200000	USD
CY2018Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1900000	USD
CY2019Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5029000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1330000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	184000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5598000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	600000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1701000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5598000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1761000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	600000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3897000	USD
CY2019Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3587853	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10372899	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25867248	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28712174	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25867248	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28712174	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	66000	USD
CY2018Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	65000	USD
CY2019Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	66000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5200000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.62
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2924000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3724000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4440000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9027000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5743000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69056000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18068000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3964000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2887000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	390000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	252000	USD
CY2018Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1479000	USD
CY2019Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	800000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	574000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	30000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2018Q1	us-gaap	Lease Cost LeaseCost	0	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	157000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	822000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	201000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	621000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	50000	USD
CY2015Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P11M23D
CY2018Q4	us-gaap	Liabilities Liabilities	27366000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	32085000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4010000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3234000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27329000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	32085000	USD
CY2018Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-130000	USD
CY2019Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2018Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2019Q1	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19885000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6267000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	213000	USD
CY2019Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48070000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4436000	USD
CY2018Q4	us-gaap	Notes Issued1 NotesIssued1	4000000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4010000	USD
CY2019Q1	us-gaap	Notes Payable Current NotesPayableCurrent	4010000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2150000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	250000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18138000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7678000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-69056000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-18068000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-69122000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18068000	USD
CY2018Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	46000	USD
CY2019Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	20986000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	13632000	USD
CY2018Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	158000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	191000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	800000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20986000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13632000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	772000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	772000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-451200000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-433146000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-451214000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	600000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	645000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	978000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	777000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	201000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	138000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	93000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	939000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	649000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-50000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	USD
CY2019Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	200000	USD
CY2018Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	157000	USD
CY2019Q1	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	717000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	813000	USD
CY2018Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2019Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	20000000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	6273000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1197000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1197000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	593000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	527000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11959000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7889000	USD
CY2018Q1	us-gaap	Restricted Cash RestrictedCash	569000	USD
CY2019Q1	us-gaap	Restricted Cash RestrictedCash	416000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	431000	USD
CY2019Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	416000	USD
CY2018Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	802000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	688000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1962000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.764
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.025
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.15
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3136030	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	59000	shares
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	121315000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	5226000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-289546000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-18292000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-23356000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-28851000	USD
CY2018Q1	us-gaap	Stockholders Equity Change In Reporting Entity StockholdersEquityChangeInReportingEntity	1946000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	166.7000
CY2018Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	223000	USD
CY2018Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	66000	USD
CY2019Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2018Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	14100000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14974458	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26883734	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions in excess of federally insured limits. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</font></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;"> S</font><font style="font-family:inherit;font-size:10pt;">ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but not limited to, the discount rate used in estimating the fair value of the operating lease right-of-use assets and operating lease liabilities, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants issued, the useful lives of property and equipment, the recoverability of long-lived assets, preclinical and clinical trial accruals, assumptions used in estimating the fair value of stock-based compensation expense and other contingencies. The Company’s assumptions regarding the measurement of the Series D 2X liquidation preference and stock-based compensation are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#s9E118FCC1EC65C83A122CB6441DCB3D3"><font style="font-family:inherit;font-size:10pt;">Note 5 — Fair Value of Financial Instruments</font></a><font style="font-family:inherit;font-size:10pt;"> and </font><a style="font-family:inherit;font-size:10pt;" href="#s25E8DDB92BB8568F9B6DFB45F051F7DC"><font style="font-family:inherit;font-size:10pt;">Note 11 — Stock-based Compensation, </font></a><font style="font-family:inherit;font-size:10pt;">respectively. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001618835-19-000084-index-headers.html	Edgar Link	pending
0001618835-19-000084-index.html	Edgar Link	pending
0001618835-19-000084.txt	Edgar Link	pending
0001618835-19-000084-xbrl.zip	Edgar Link	pending
evfm-20190331.xml	Edgar Link	completed
evfm-20190331.xsd	Edgar Link	pending
evfm-20190331_cal.xml	Edgar Link	unprocessable
evfm-20190331_def.xml	Edgar Link	unprocessable
evfm-20190331_lab.xml	Edgar Link	unprocessable
evfm-20190331_pre.xml	Edgar Link	unprocessable
evfm-331201910xq.htm	Edgar Link	pending
evfm-3312019ex101.htm	Edgar Link	pending
evfm-3312019ex311.htm	Edgar Link	pending
evfm-3312019ex312.htm	Edgar Link	pending
evfm-3312019ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lynchs2019consultinga_image1.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2019 Q2 Form 10-Q Financial Statement

#000161883519000084 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2019 Q2 Form 10-Q Financial Statement

#000161883519000084 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm